Final Programme 2019

42 EDUCATIONAL SEMINARS Saturday, 27 April 2019 ES-04 Educational Seminar 16:15–17:15 Auditorium IV Recommendations for therapy in school Chairs: S. Walitza, Switzerland & R. Drechsler, Switzerland School-based interventions. Richards et al. (2015) focus on three possible levels of school-based interventions: a) on the structure of the class b) on the teacher/educational staff and c) on the student a) Interventions on the class structure are e.g. classroom design (low-irritation, few distraction possibilities), type of class leadership by the teacher (alternating phases, varied, group amplifier plans) or use of short phases of physical activity b) Interventions at the level of the teacher are primarily education on ADHD, school lesson design tailored to ADHD children (e.g. stronger tutoring programs for weaker students or PC-based instructions), and the use of interactive strategies by the teacher c) student-centered interventions are e.g. training methods such as PC-based cognitive training, which can be carried out at school but are not necessarily tied to the school setting, the training of self-management and intention- implementation The online Help guide (Segal and Smith, 2019) is an example focusing on support the parents to work and communicate with the school, to make individual behavioural plans “The Daily Report Card” to support the child. A special challenge of the seminar are the different legal aspects and school systems of the different countries. For this issue comments and discussion of the participants are of special interest. ES-05 Educational Seminar 16:15–17:15 Auditorium III ADHD and problematic internet use: Treatment options Chair: S. H. Kollins, USA Patients with ADHD are at increased risk for a wide range of addictive disorders, including cigarette smoking/tobacco use, cocaine use, and cannabis use. In recent years it has also been acknowledged that internet addiction is a real phenomenon with many features similar to other substance use disorders. The purpose of this educational activity is to survey the literature and describe clinical experience relevant to understanding problematic internet use among patients with ADHD. Developmental considerations will be discussed, along with treatment options. Learning Objectives 1. Describe the similarities and differences between problematic internet use/addiction and substance use disorders 2. Understand the clinical features that may place patients with ADHD at increased risk for problematic internet use 3. Evaluate the evidence for different approaches to preventing and treating problematic internet use among patients with ADHD ES-06 Educational Seminar 16:15–17:15 Room 1.02 Treatment of ADHD and substance abuse Chair: J. A. Ramos Quiroga, Spain ADHD is considered a risk factor for the development of substance use disorders (SUD). More than 30% of patients with ADHD will develop lifetime SUD. Specifically, ADHD and cannabis use are partly determined by genetic factors; the heritability of ADHD is estimated at 70-80% and of cannabis use initiation at 40-48%. Recent study found that ADHD is causal for lifetime cannabis use, with an odds ratio of 7.9 for cannabis use in individuals with ADHD in comparison to individuals without ADHD. On the other hand, about 20- 25% of adult SUD patients fulfill criteria for ADHD. In an international multicenter study, the IASP study, the overall prevalence of adult ADHD in treatment seeking SUD patients was still as high as 14%. It is essential the correct assessment of psychiatric comorbidity in ADHD because the patient's comorbidity profile will influence treatment planning. Simultaneous and integrated treatment of ADHD and SUD, using a combination of pharmaco- and psychotherapy, is recommended. Long-acting methylphenidate, extended- release amphetamines, and atomoxetine with up-titration to higher dosages may be considered in patients unresponsive to standard doses. The seminar provides an overview of the treatment of ADHD in patients with SUDs. The multiple challenges that commonly appear during the treatment of this comorbidity are discussed.